Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284979 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
A Phase 3 study of Obesity, sponsored by Kailera.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT07284979: Recruiting Phase 3 study of Obesity, sponsored by Kailera.
NCT07284979 is a Phase 3 study of Obesity that is actively recruiting participants, run by Kailera. The registered enrollment target is 1,200 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284979, a Phase 3 study of Obesity, is actively recruiting participants, sponsored by Kailera.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KAI-9531
- DRUG Semaglutide
Study Locations (20)
Arizona
- Kailera Clinical Site - Glendale
- Kailera Clinical Site - Phoenix
California
- Kailera Clinical Site - Northridge
- Kailera Clinical Site - Oceanside
Connecticut
- Kailera Clinical Site - Hamden
- Kailera Clinical Site - Stamford
Arkansas
- Kailera Clinical Site - Little Rock
Florida
- Kailera Clinical Site - Orange City
Georgia
- Kailera Clinical Site - Albany
Illinois
- Kailera Clinical Site - Chicago
Kansas
- Kailera Clinical Site - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2028-04-17 |
| Phase | Phase 3 |
What NCT07284979 shows while recruiting
NCT07284979 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07284979 names 20 study sites across 17 states, led by Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07284979 about?
NCT07284979 is a clinical study titled "Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes". The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
What is the current status of trial NCT07284979?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2025-12-30. Estimated completion is 2028-04-17.
What conditions does trial NCT07284979 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07284979?
The interventions under investigation include: Placebo (DRUG), KAI-9531 (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07284979?
This trial is sponsored by Kailera, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284979 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284979's enrollment target sits among peer trials
1,200 66th of 1053 higher than 987 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI